Co-Diagnostics Inc (CODX)

[Opti Mist]

Co-Diagnostics: A+ Student Faces New Tests
Mar. 12, 2021 10:45 AM ETCo-Diagnostics, Inc. (CODX)3 Likes
Summary
Co-Diagnostics went public in 2017 with a proprietary infectious disease testing technology and a clever strategy.
During its early rollout, Co-Diagnostics' strategy failed to generate noticeable revenues.
As 2020 unfolded, the pandemic both validated Co-Diagnostics' technology and its revenue potential.
Surprisingly, Co-Diagnostics is maintaining its appeal even as the pandemic starts to wind down.
I first became interested in Co-Diagnostics (CODX) because of its outstanding A+ quant grades for value, growth, and profitability on 12/22/20. These grades set it apart from its Healthcare peers; only two others were able to match its report.

Recently I checked back to see how it was faring. As I write on 3/11/21 its report is holding strong, A+'s across all three terrains as shown below:

Co-Diagnostics In this article I will drill down on Co-Diagnostics, explaining why I agree from an operational standpoint with its stellar quant grades. I take an optimistic view of its prospects. Those who have room in their portfolio for a highly speculative micro-cap with good prospects should find that Co-Diagnostics just fills the bill.

https://seekingalpha.com/article/4413467-co-diagnostics-student-faces-new-tests